Loading
A single change in a histone protein that defines diffuse midline glioma, the childhood brain tumour with the fewest treatment options, and now the target of the first approved drug for it.
Lysine-to-methionine mutation at position 27 of histone H3 (H3F3A or HIST1H3B) causes global loss of H3K27 trimethylation. Defines WHO grade 4 diffuse midline glioma (including DIPG), median survival ~11 months, radiotherapy the only proven therapy until dordaviprone (2025). GD2 is overexpressed, enabling CAR-T.
Showing the molecule this term concerns: Dordaviprone.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares National Brain Tumor Society (NBTS), Epigenetic reprogramming, The brain: barrier and sanctuary, DNA methylation profiling.
Shares Develop drugs in children first when the target is a children's target, DNA methylation profiling, Glioma & glioblastoma.
Shares Ependymoma molecular groups (PF-A, PF-B, ZFTA, YAP1, MYCN), Spinal cord tumours (intramedullary and intradural), Epigenetic progenitor theory: cancer without a first mutation, Epigenetic reprogramming.
Shares National Brain Tumor Society (NBTS), Epigenetic progenitor theory: cancer without a first mutation, Epigenetic reprogramming, The brain: barrier and sanctuary.
Shares Ependymoma molecular groups (PF-A, PF-B, ZFTA, YAP1, MYCN), DNA methylation profiling, Glioma & glioblastoma.
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), The brain: barrier and sanctuary, Glioma & glioblastoma.
Shares Dordaviprone, CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), Diffuse midline glioma, H3 K27-altered (including DIPG), The brain: barrier and sanctuary.
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), Diffuse midline glioma, H3 K27-altered (including DIPG).